...
首页> 外文期刊>OncoTargets and therapy >Effects of proton pump inhibitors on reversing br /multidrug resistance via downregulating V-ATPases/PI3K/Akt/mTOR/HIF-1α signaling pathway br /through TSC1/2 complex and Rheb in human gastric adenocarcinoma cells in vitro and in vivo
【24h】

Effects of proton pump inhibitors on reversing br /multidrug resistance via downregulating V-ATPases/PI3K/Akt/mTOR/HIF-1α signaling pathway br /through TSC1/2 complex and Rheb in human gastric adenocarcinoma cells in vitro and in vivo

机译:质子泵抑制剂通过下调V-ATPases / PI3K / Akt / mTOR /HIF-1α信号通路通过TSC1 / 2复合物和Rheb逆转人胃腺癌细胞中
多药耐药性的作用体内

获取原文
           

摘要

Background: Our study aimed to explore the effects of PPIs on reversing multidrug resistance (MDR) to chemotherapy in gastric cancer by inhibiting the expression of V-ATPases and the PI3K/Akt/mTOR/ HIF-1α signal pathway. Methods: The gastric cancer cell lines SGC7901 and the multidrug resistance cell lines SGC7901/MDR were pretreated by the pantoprazole or the esomeprazole, respectively. Real-time PCR was used to determine mRNA levels, and western blotting and immunofluorescent staining analyses were employed to determine the protein expressions and intracellular distributions of the V-ATPases, PI3K, Akt, mTOR, HIF-1α, P-gp and MRP1 before and after PPIs pretreatment. SGC7901/MDR cells were planted on the athymic nude mice. Then the effects of PPZ pretreatment and/or ADR were compared by determining the tumor size, tumor weight and nude mice weight. Results: PPIs pretreatment could inhibit mRNA levels of V-ATPases, MDR1 and MRP1, PI3K, Akt, mTOR and HIF-1α. PPIs inhibited V-ATPases and down-regulated the expressions of P- gp and MRP1. And further to block the expression of mTOR by Rapamycin could obviously inhibit the expressions of HIF-1α, P-gp and MRP1 in a dose-dependent manner. Therefore, PPIs inhibited the expressions of V-ATPases and then reversed MDR of the chemotherapy in gastric cancer by inhibiting P-gp and MRP1, and it could be speculated that the mechanism might be closely related to down-regulating the PI3K/Akt/mTOR/HIF-1α signaling pathway. Meanwhile, PPIs also could inhibit the expressions of TSC1/TSC2 complex and Rheb which might be involved into regulating the signaling pathway intermediately. The weight growth rate of the mice bearing tumor in the treatment group was lower than that of the nude mice in the normal group, while the weight growth rate of the mice in control group was significantly lower than that of the normal group and the treatment group, presenting a downward trend. Conclusion: Therefore, PPIs inhibited the expressions of V-ATPases and then reversed MDR of the chemotherapy in gastric cancer by inhibiting P-gp and MRP1, and it could be speculated that the mechanism might be closely related to down-regulating the PI3K/Akt/mTOR/HIF-1α signaling pathway, and also to inhibiting the expressions of TSC1/TSC2 complex and Rheb which might be involved into regulating the signaling pathway intermediately.
机译:背景:我们的研究旨在通过抑制V-ATPases的表达和PI3K / Akt / mTOR /HIF-1α信号通路来探讨PPI对胃癌化疗多药耐药性(MDR)的逆转作用。方法:分别用the托拉唑或埃索美拉唑对胃癌细胞SGC7901和多药耐药细胞SGC7901 / MDR进行预处理。实时荧光定量PCR检测mRNA水平,Western印迹和免疫荧光染色分析确定V-ATPases,PI3K,Akt,mTOR,HIF-1α,P-gp和MRP1的蛋白表达和细胞内分布。在PPI预处理之后。将SGC7901 / MDR细胞种植在无胸腺裸鼠上。然后通过确定肿瘤大小,肿瘤重量和裸鼠体重比较PPZ预处理和/或ADR的作用。结果:PPI预处理可抑制V-ATPases,MDR1和MRP1,PI3K,Akt,mTOR和HIF-1α的mRNA水平。 PPI抑制V-ATPase,并下调P-gp和MRP1的表达。雷帕霉素进一步阻断mTOR的表达可明显抑制HIF-1α,P-gp和MRP1的表达,且呈剂量依赖性。因此,PPI通过抑制P-gp和MRP1抑制胃癌中V-ATPases的表达,进而逆转化疗的MDR,推测其机制可能与下调PI3K / Akt / mTOR密切相关。 /HIF-1α信号通路。同时,PPIs也可能抑制TSC1 / TSC2复合物和Rheb的表达,可能参与中间调节信号通路。治疗组荷瘤小鼠的体重增长速度低于正常组的裸鼠,而对照组小鼠的体重增长速度明显低于正常组和治疗组。 ,呈现下降趋势。结论:因此,PPIs通过抑制P-gp和MRP1抑制胃癌中V-ATPases的表达,进而逆转化疗的MDR,可以推测其机制可能与下调PI3K / Akt密切相关。 / mTOR /HIF-1α信号通路,并抑制TSC1 / TSC2复合体和Rheb的表达,这可能与中间调节信号通路有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号